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Abstract
Background: There is momentum internationally to improve coordination of complex care pathways. Robust
evaluations of such interventions are scarce. This paper evaluates the cost-utility of cancer care coordinators for
stage III colon cancer patients, who generally require surgery followed by chemotherapy.
Methods: We compared a hospital-based nurse cancer care coordinator (CCC) with ‘business-as-usual’ (no
dedicated coordination service) in stage III colon cancer patients in New Zealand. A discrete event microsimulation
model was constructed to estimate quality-adjusted life-years (QALYs) and costs from a health system perspective.
We used New Zealand data on colon cancer incidence, survival, and mortality as baseline input parameters for the
model. We specified intervention input parameters using available literature and expert estimates. For example, that
a CCC would improve the coverage of chemotherapy by 33 % (ranging from 9 to 65 %), reduce the time to surgery
by 20 % (3 to 48 %), reduce the time to chemotherapy by 20 % (3 to 48 %), and reduce patient anxiety (reduction
in disability weight of 33 %, ranging from 0 to 55 %).
Results: Much of the direct cost of a nurse CCC was balanced by savings in business-as-usual care coordination.
Much of the health gain was through increased coverage of chemotherapy with a CCC (especially older patients),
and reduced time to chemotherapy. Compared to ‘business-as-usual’, the cost per QALY of the CCC programme
was $NZ 18,900 (≈ $US 15,600; 95 % UI: $NZ 13,400 to 24,600). By age, the CCC intervention was more cost-effective for
colon cancer patients < 65 years ($NZ 9,400 per QALY). By ethnicity, the health gains were larger for Māori, but so too
were the costs, meaning the cost-effectiveness was roughly comparable between ethnic groups.
Conclusions: Such a nurse-led CCC intervention in New Zealand has acceptable cost-effectiveness for stage III colon
cancer, meaning it probably merits funding. Each CCC programme will differ in its likely health gains and costs, making
generalisation from this evaluation to other CCC interventions difficult. However, this evaluation suggests that CCC
interventions that increase coverage of, and reduce time to, effective treatments may be
cost-effective.
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Background
Cancer care can be complex for patients to navigate.
Partly in response to this, there has been an increasing
emphasis on cancer care coordinator roles (CCC; also
known as patient navigators, key workers, one to one
support workers, liaison officers, coordination officers,
and case management nurses) to improve patient out-
comes within cancer care services, especially among
lower socio-economic populations [1, 2]. Providing bet-
ter coordinated care for cancer patients has been identi-
fied by the National Institute for Health and Care
Excellence (NICE) as essential to enabling the needs of
patients to be identified and met [3]. CCC roles vary in
terms of the stage of cancer management on which they
focus, ranging from access to cancer screening, to co-
ordination of care following diagnosis, to survivorship
support. Evidence of effectiveness is starting to emerge
with regards to improving uptake of cancer screening,
earlier stage at diagnosis, timeliness of care, adher-
ence to treatment, hospital utilisation and patient sat-
isfaction [4–13].
Expenditure on cancer care is increasing at an alarm-
ing rate worldwide. This increase highlights the need
for changes to models of care delivery and a need for
evaluations to assist with determining and prioritising
cost-effective interventions – including service config-
urations in addition to pharmaceuticals and discrete
treatments [14]. There are examples of economic ana-
lyses of CCC type interventions conducted elsewhere
[15–17], but to our knowledge no nurse-led hospital-
based cancer coordination intervention has been sub-
jected to a rigorous cost-utility analysis [18]. There is
considerable uncertainty in the effect and cost of
service-level interventions. However, decision-makers
still need to prioritise where cancer control resources
are deployed. This paper brings together these
agendas, using microsimulation modelling incorporat-
ing the considerable uncertainties.
Given the diverse nature of CCC programmes, it was
not possible to evaluate them generally across all cancer
sites. We thus focused on stage III colon cancer for
three reasons. First, colon cancer is a ‘priority’ cancer for
which CCC programmes are emerging; second, the
treatment pathway requires both surgery and chemo-
therapy and therefore more coordination may be re-
quired than (say) early stage colon cancer for which
surgery alone is considered curative; and third, there is a
consensus that adjuvant chemotherapy should be offered
following surgery for stage III disease.
There is increasing concern about social inequalities in
cancer survival and outcomes, and New Zealand is no
exception. For example, Māori (the indigenous popula-
tion) have worse survival from cancer that is not fully
explained by stage at presentation [19], including for
colon cancer [20]. Part of the reason for these social in-
equalities in survival is likely to include differences in re-
ceipt of treatments and waiting times to treatments [21],
which may be remedied through the CCC programmes.
The objective of this paper is to determine the cost-utility
of a CCC intervention in stage III colon cancer, including
differences by patient age, sex, ethnicity, and socio-
economic status (collectively called socio-demographics
from here on). The CCC in question is a clinical nurse spe-
cialist who provides support and information to the patient,
coordinates the provision of treatment, and identifies and
addresses barriers to care.
Methods
Methods are briefly outlined here; more detail is pro-
vided in the Additional files. A health system perspective
was used; costs and benefits beyond the health system
(e.g. productivity costs) were out of scope. Participants
were patients with stage III colon cancer in New
Zealand, modelled till death, or age 110 years. Costs
were in 2011 New Zealand dollars (with conversion of
the main incremental cost-effectiveness ratio to US
dollars and UK pounds using exchange rates as of March
2013). A 3 % per annum discount rate was applied to
costs and benefits.
Intervention and comparator definition
The CCC intervention was defined as a hospital-based
clinical nurse specialist (CNS) who is the main point of
contact for the patient and a key point of contact for
health professionals involved in the patient’s care. This
begins at the point of provisional diagnosis of colon can-
cer and continues until initiation of chemotherapy for
patients with confirmed stage III colon cancer. The CCC
role would include: providing information and support
for the patient, identifying and addressing patient bar-
riers to accessing care (transport/financial/social), coord-
inating arrangements for pre-operative assessments and
hospital admission, optimising post-operative care, track-
ing investigations and appointments, ensuring the patient
is discussed at a multidisciplinary team meeting, making
referrals as necessary, and acting on any administrative
delays. (See Additional file 1 for more detail on the CCC
intervention).
We specified that the health gain from a CCC inter-
vention would be via four effects: reducing time from
provisional diagnosis to surgery (and associated im-
proved survival), reducing time from surgery to chemo-
therapy (and associated improved survival), improving
the coverage of chemotherapy and associated improved
survival (there was little room for improvement in
coverage of surgery) and reducing patients’ anxiety dur-
ing diagnosis and treatment (thus improving patients’
quality of life). How these effects were quantified is
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described in the Input Parameter section below and in
Additional file 2. We acknowledge that treatment cover-
age and waiting times are also influenced by other re-
source constraints (e.g. theatre space/time, staffing, and
ward space), and a CCC per se will have little or no im-
pact on these structural barriers. It should also be noted
that this intervention was conceptualised based on the
New Zealand context.
The comparator was business-as-usual i.e. no dedi-
cated CCC programme as is common in many countries.
In a business-as-usual scenario, needs assessment is pro-
vided by a number of different nurses, doctors or other
health professionals at various points along the cancer
care pathway, followed by referrals to other health ser-
vices. No one individual is responsible for tracking refer-
rals, investigations or appointments and acting on
delays, with potential for tasks to be duplicated or
missed. (See Additional file 1 for more detail on the
comparator).
Model overview
We constructed a discrete event simulation model (DES; a
form of microsimulation) to address our research question.
Modelling was conducted in Tree Age Pro 2012. A DES
model was chosen as it allows “jumping” from the time of
one ‘event’ to the time of the next event, making it particu-
larly useful when patients are subject to competing events.
There were four competing events in our case: time to
death from colon cancer, time to death from other causes,
time to surgery, and time to start of chemotherapy. The
first three ‘compete’ at diagnosis. If the patient makes it to
surgery, then deaths from cancer, death from other causes
and time to chemotherapy are the three competing events.
And if the patient makes it to chemotherapy, the two
(absorbing) death states are the remaining competing
events (see Figure 1 for model structure overview). The
main model outputs were health gain (in quality-adjusted
life-years or QALYs), incremental costs, and incremental
cost-effectiveness ratios (ICERs).
Input parameters
Selected input parameters are shown in Tables 1 and 2,
and summarised in the text below. A full input parameter
table and further explanation is provided in Additional
file 2. Most input parameters have a best estimate
(‘expected value’). To capture the lack of perfect
knowledge around each input parameter (input parameter
uncertainty), a probability distribution around the
expected value was usually defined.
Baseline incidence, survival and mortality data
The estimated incidence rates of colon cancer were cal-
culated across all combinations of sex, age, ethnicity
(Māori, non-Māori), and socio-economic status (three
levels) from New Zealand Cancer Registry data. These
were disaggregated by ethnicity and deprivation using
linked census-cancer data (as described elsewhere) [22].
This was further restricted to those with stage III colon
cancer, and disaggregated by receipt of surgery and
chemotherapy [23].
Colon cancer mortality rates (by time since diagnosis
and socio-demographics) were estimated using excess
mortality rate modelling on cancer registry data linked
to mortality data. These rates were then adjusted to be
specific to stage III colon cancer and receipt of surgery
and chemotherapy (see Additional file 2). Background
population mortality rates were derived from socio-
demographic life tables [24].
Baseline waiting times to surgery and chemotherapy, and
baseline coverage of chemotherapy
Baseline waiting times to surgery and waiting times from
surgery to chemotherapy (without a CCC) by socio-
demographics were estimated using data from a previous
New Zealand hospital notes review study of over 600 colon
cancer patients diagnosed between 1996 and 2003 [20].
Baseline coverage of chemotherapy was calculated for
those who were eligible and did not refuse treatment,
by age and socio-demographic group (see Additional
file 2).
Effect of a CCC
As mentioned earlier, we specified that the health gain
from a CCC intervention would be via four effects: redu-
cing time from provisional diagnosis to surgery, reducing
time from surgery to chemotherapy, improving the
coverage of chemotherapy (there was little room for
improvement in coverage of surgery) and reducing
Fig. 1 Discrete event simulation (DES) model structure
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patients’ anxiety during diagnosis and treatment (thus
improving patients’ quality of life).
We undertook systematic literature searches to deter-
mine the impact a CCC might have on increasing
chemotherapy coverage, reducing waiting times (to sur-
gery and from surgery to chemotherapy), and improving
quality of life for cancer patients (see Additional file 3).
Evidence for most of these was sparse. The only available
source for estimating the impact of a CCC on improving
receipt of chemotherapy was a study by Goodwin et al.,
assessing a CCC-type intervention in older patients with
breast cancer in the United States [25]. Similarly, in
order to estimate the impact of a CCC on reducing time
from diagnosis to surgery as well as from surgery to
chemotherapy, we drew on a retrospective case series ana-
lysis by Haideri et al., [10] again assessing the effect of a
CCC-type intervention in women with breast cancer. The
impact of a CCC on anxiety reduction and thus quality of
life was estimated based on a study by Ferrante et al., [8]
looking at the effect of a patient navigator on reducing anx-
iety after an abnormal mammogram. The available evi-
dence was complemented by consultation with health
professionals from different cancer centres (medical on-
cologist, colorectal surgeon, oncology nurses) in order to
source estimates and specify distributions.
The key parameters for effect of a CCC are showed
in Table 1, with more detail provided in Additional
file 2. We deliberately specified generous uncertainty
for each of these input parameters given the lack of
robust published evidence. For example, we estimated
that a CCC would improve the coverage of chemother-
apy by 33 % (but with the 95 % uncertainty interval
ranging from 9 to 65 %), and reduce the time between
surgery and chemotherapy by 20 % (ranging from 3 to
Table 1 Selected effect size parameters used in the model (greater detail and full list provided in Additional file 2)
Variable name Variable definition Source, derivation and application Expected value and 95 %
uncertainty interval
Effect of a CCC on increasing receipt of chemotherapy




receiving surgery only to surgery
plus chemotherapy
Goodwin et al. 2003 [25] and expert
estimates
0.33 (0.09 to 0.65)
See Additional file 2 Beta distribution
Hazard ratio (HR) for
chemotherapy
Effect of chemotherapy with oxaliplatin
on breast cancer mortality
Sargent et al. 2009 [36] 1: 0.72 (0.61 to 0.85)
De Gramont et al. 2007 [37] 2: 0.78 (0.63 to 0.98)
Andre et al. 2004 [38] Log normal distribution
(Effect of chemotherapy without
oxaliplatin on breast cancer mortality
considered as scenario analysis)
See Additional file 2
Product of two HRs: 1: effect of chemo
without oxaliplatin compared to no
chemo multiplied by 2: effect of chemo
with oxaliplatin compared to without
oxaliplatin
Effect of a CCC on reducing wait
times to treatments
Reduction in days to surgery Proportionate reduction in days to
surgery due to a CCC
Haideri et al. 2011 [10] and expert
estimates
0.20 (0.03 to 0.48)
See Additional file 2 Beta distribution
Reduction in EMR per day
decrease in time from diagnosis
to surgery
Reduction in cancer excess mortality
rate (EMR) per day decrease in time
from diagnosis to surgery (i.e. the
effect of getting surgery faster on
colon cancer mortality)
No direct evidence. Estimated using
protocol, [39] Whyte et al. 2011, [40]
Tappenden et al. 2007 [41]
0.9972 ratio decrease in EMR
per day quicker to surgery
(0.9955 to 0.9987)
Log normal distributionSee Additional file 2
Reduction in days to
chemotherapy
Proportionate reduction in average
days from surgery to chemotherapy
due to a CCC
Expert estimates 0.20 (0.03 to 0.48)
See Additional file 2 Beta distribution
Reduction in EMR per day
decrease in time from surgery
to chemotherapy
Reduction in cancer excess mortality
rate (EMR) per day decrease in time
from surgery to chemotherapy (i.e.,
the effect of getting chemotherapy
faster on colon cancer mortality)
Biagi et al. 2011 [42] 0.9953 ratio decrease in EMR
per day quicker to chemotherapy
(0.9983 to 0.9969)See Additional file 2
Log normal distribution
Effect of a CCC on reducing colon cancer morbidity
↓DW due to CCC Reduction in disability weight (DW)
during diagnosis and treatment phase
due to a CCC reducing patient anxiety
Ferrante et al. [8] 0.67 (0.45 to 1.0)
See Additional file 2 Log normal distribution
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48 %). For practical purposes, more effort was invested
in estimating those input parameters where the
uncertainty contributed significantly to overall ICER
uncertainty (see Additional file 2 and Figs. 3 and 4 for
such ‘key’ parameters).
Quality-adjusted life-years (QALYs) and disability weights
QALYs use many different health status valuation
methods e.g. EuroQol (EQ5D) and the Health Utilities
Index questionnaire. We used disability weights (DWs,
where 0 is perfect health and 1.0 is equivalent to death)
adapted from the Global Burden of Disease 2010 [26, 27].
Accordingly, we use the term QALYDW in the Methods
and Results section of this paper (but default to QALYs
elsewhere).
Disability weights (DWs) were applied separately to
four phases of colon cancer disease, by merging the
recent Global Burden of Disease 2010 DWs (given for
cancers overall) [27] with the relative difference in DW
by cancer in the Australian BDS colorectal cancer model
[26]. The phases were diagnosis and treatment, remis-
sion, pre-terminal and terminal, and the durations and
attendant DWs are shown in Additional file 2. We also
allow for sex- and age-specific background morbidity,
using the expected level of background morbidity for all
diseases combined from a recent New Zealand burden
of disease study [28]. For example, for a 70–74 year old
with an expected background morbidity equivalent to a
DW of 0.3 and who was in the diagnosis and treatment
(DT) phase of colon cancer (DW of DT phase = 0.288),
their QALYDW per annum was (1–0.3)X (1–0.288) =
0.498. QALYsDW continued to be tallied in the model
beyond the cure time (eight years post diagnosis) to
death from other causes, or age 110 if still alive.
Health system costs
The health system costs were determined by strata of
sex and age using a dataset of (nearly) all New Zealanders
with their health system events (e.g. hospitalisation, lab
test) all ascribed a cost. Following Van Baal et al. [29], we
separately determined expected costs for those in the last
six months of life. A critical health system cost for our
model was that for chemotherapy, as many people moved
from having surgery only to receiving chemotherapy post-
operatively. We estimated the cost of chemotherapy at
$NZ 17,812 per six month treatment per patient using a
bottom-up costing approach including the cost of the
pharmaceuticals, outpatient attendance and overheads
(see Additional file 4). As with QALYsDW, health system
costs continued to be tallied in the model beyond the cure
time (eight years post diagnosis) to death from other
causes or age 110 if still alive.
Incremental cost of CCC
The CCC intervention pathway was specified following
review of the literature and consultation with local
health care professionals, then costed (Additional files 1
and 5). The incremental cost of the CCC intervention is
the cost of the care pathway with a CCC in place minus
Table 2 Selected cost parameters used in the model (greater detail and full list provided in Additional files 5 and 4)
Variable name Variable definition Source, derivation and application Expected value and 95 %
uncertainty interval
Incremental CCC cost from
diagnosis to surgery
Incremental cost of CCC programme from
provisional diagnosis to surgery (difference
in costs for pathway of care with CCC minus
pathway of care in business-as-usual comparator)
Consultation with local health care
professionals (costed based on
average salaries + 50 % overheads)
$64.03 per patient
($29.42 to $98.64)
Normal distributionSee Additional file 5
Incremental CCC cost from
surgery to start of chemotherapy
Incremental cost of CCC programme from
surgery to start of chemotherapy
Consultation with local health care
professionals (costed based on
average salaries + 50 % overheads)
$5.00 per patient
($-10.39 to $20.39)
Normal distributionSee Additional file 5
Cost of chemotherapy per
patient










See Additional file 4
Dietician costs Additional costs from dietician referrals
precipitated by a CCC
Expert estimates $115.89 per patient ($81.38
to $141.16)
Referrals estimated to increase by
50 %, 2 contacts per referral. See
Additional files 5 and 4
Gamma distribution
Social worker costs Additional costs from social worker
referrals precipitated by a CCC
Referrals estimated to increase
by 42 %, 6 contacts per referral.
$327.95 to $483.97
See Additional files 5 and 4 Gamma distribution
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the cost of the care pathway in the business-as-usual
comparator. To determine the time spent on coordinat-
ing activities where no CCC exists in the business-as-
usual comparator, we calculated the cost per minute of
coordinating activity being carried out based on the
average salaries (plus 50 % overheads) of the personnel
carrying out the activity. The incremental cost of the
CCC programme itself is modest (e.g. expected values of
$64.03 and $5.00 from provisional diagnosis to surgery
and between surgery and chemotherapy, respectively).
This is because whilst a CCC is introduced, other re-
sources such as surgeon and nurse time previously spent
on coordinating activities are released for use elsewhere.
We also included the costs for increased allied health re-
ferrals precipitated by the CCC.
Analyses
There is often considerable uncertainty in estimates of
cost, health gain, and cost-effectiveness. This uncertainty
comes from two sources: input parameter uncertainty
(uncertainty about input parameters due to lack of per-
fect knowledge) and model structure uncertainty (uncer-
tainty about the assumptions implicit in the model
structure). Additionally, results also vary due to hetero-
geneity (differences by patient or population characteris-
tics such as age, sex, ethnicity, and socio-economic
status) [30]. We conducted a range of analyses to ad-
dress input parameter uncertainty, heterogeneity, and
model structure uncertainty. The types of analyses we
conducted are described briefly below:
Main model analysis
Our main or full model analysis incorporates input par-
ameter uncertainty and heterogeneity. As mentioned
earlier, for input parameters where there is considerable
uncertainty, a probability distribution around the best
estimate is defined. Our main analysis captures input
parameter uncertainty through a ‘looped’ or nested
Monte Carlo simulation approach, involving millions of
simulations in total. This approach is described in detail
by Koerkamp et al. [30]. The effect of this input param-
eter uncertainty is then presented as 95 % uncertainty
intervals (UIs) for QALYsDW, incremental costs, and
ICERs. These main results’ can be presented for all stage
III colon cancer patients combined, but also separately
by heterogeneous patient types (e.g. different ethnic
groups, young and old) – so called ‘heterogeneity
analyses’.
Expected value analysis
This analysis uses only expected or central values for
each input parameter; it does not allow for input param-
eter uncertainty. Such analyses are much quicker to run.
We used this approach for a number of sensitivity and
scenario analyses.
Ethnic equity analysis
The main analysis allows for variation in survival, mor-
bidity and baseline times to event by ethnic group.
While this approach uses the best available data, it also
means that we value a life saved for Māori less than that
for non-Māori. This is due to the fact that the higher ex-
pected background morbidity and lower life expectancy
for Māori limits the QALYsDW that can be gained.
Therefore, we also undertook an ‘equity analysis’ where
we applied the non-Māori least deprived background
mortality rates and the non-Māori average background
morbidity to Māori.
Scenario analyses
We re-ran models for a range of scenarios to assess the
impact of changing various model structure assump-
tions, such as the discount rate.
One-way sensitivity analyses
We also undertook a range of one-way sensitivity ana-
lyses and Tornado plots [31], using the 2.5th and 97.5th
percentile values of input parameters, to assess which in-
put parameters contributed the most to uncertainty in
the model outputs (i.e. QALYDW, cost and ICER).
Ethics
This analysis was conducted within the Burden of Disease
Epidemiology, Equity, and Cost-Effectiveness (BODE3) re-
search programme. The BODE3 programme is in compli-
ance with the Helsinki Declaration. The Health and
Disability Ethics Committee confirmed ethical approval
was not required for BODE3 under section 11.8 and 11.9
of the New Zealand National Ethics Advisory Committee
(NEAC) Guidelines for Observational Studies, as ethical
approval is not required for secondary use of data for the
purpose of quality assurance or outcome analysis when
undertaken by those employed by the health service pro-
vider holding the information.
Results
Main model analysis
Figure 2 and Table 3 present the findings from our main
model analysis. They depict uncertainty in incremental
costs and QALYsDW gained, due to input parameter un-
certainty (model 1 in Table 3 and solid markers in Fig. 2).
They additionally depict variation due to heterogeneity
across sex, age, ethnicity and deprivation (model 2 in
Table 3 and crosses in Fig. 2). We focus on the former
here, and consider heterogeneity below.
The mean estimated QALYsDW gain per patient was
0.121 (95 % UI 0.070 to 0.185), and the incremental cost
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$NZ 2,271 (95 % UI $1,225 to $3,641). Accordingly, the
ICER was $NZ 18,881 per QALYsDW gained (≈ $US
15,600, ≈ £UK 10,300) with relatively narrow uncertainty
($NZ 13,442 to $24,610) compared to the uncertainty in
both QALYsDW and cost due the strong correlation of
increasing cost with increasing QALYsDW (depicted
graphically as the eclipse cloud in Fig. 2). This is because
a key health benefit of CCC is increased coverage of
chemotherapy, which is also a key cost driver.
Heterogeneity analysis
There is a much larger scatter of points on the cost-
effectiveness plane in Fig. 2 when variation by patient
heterogeneity (sex, age, ethnicity and deprivation) in
addition to input parameter uncertainty is depicted.
Model outputs vary by these socio-demographics due to
differences in inputs of time to event (surgery, chemo-
therapy, death from cancer and death from other causes)
and expected population morbidity. Table 4 shows the
expected value analysis outputs by socio-demographics.
Variation by sex is modest. However, variation by age is
large with decreased cost and (modestly) increased
QALYsDW gains among younger patients, leading to a
more favourable ICER ($9,400). By socio-economic
deprivation, the cost is greater for more deprived people,
but the QALYsDW gains less leading to a worse ICER
($22,800).
There are large differences in age structure by ethni-
city in New Zealand, so we focus on the ethnicity by age
comparisons. Within young and old, the incremental
cost and QALYsDW gained are both estimated to be lar-
ger for Māori and the ICER modestly higher for Māori
(e.g. $25,300 for Māori ≥ 65 years compared to $23,300
for non-Māori ≥ 65 years).
Scenario analyses
Table 5 shows how the findings vary for scenario ana-
lyses about model assumptions and structure. As men-
tioned earlier, for practical purposes the scenario
analyses use expected values of the input parameters,
not the full uncertainty about the input parameters.
The impact of the CCC intervention on quality of life
(by reducing the anxiety of patients) and improved sur-
vival due to getting to surgery quicker were modest
drivers of our analysis. Conversely, increased coverage of
chemotherapy and getting to chemotherapy quicker
were major drivers of model outputs. For example, ex-
cluding any effect on the number of patients getting
chemotherapy reduced the incremental cost by 64 %.
The majority of health gain and cost from a CCC oc-
curred in the post-surgical phase, due to increased
coverage of chemotherapy and decreased time to
chemotherapy. The ICER was less ($9,100) for the
Table 3 Main model analysis: incremental costs, QALYsDW








Model 1: Averaged over heterogeneity and stochastic variation; input
parameter uncertainty only
Mean $ 2,271 0.121 $ 18,881
2.5 % percentile $ 1,225 0.070 $ 13,442
Median $ 2,226 0.119 $ 18,786
97.5 % percentile $ 3,641 0.185 $ 24,610
Model 2: Averaged over stochastic variation; both heterogeneity and
input parameter uncertainty included in distribution of outputs
Mean $ 2,239 0.120 $ 23,393
2.5 % percentile $ 992 0.036 $ 6,290
Median $ 1,972 0.113 $ 17,864
97.5 % percentile $ 5,007 0.252 $ 72,041
Dollars are NZ$, for the year 2011. All costs and benefits discounted at 3 %
per annum
Fig. 2 Main model analysis cost-effectiveness plane for CCC intervention compared to business-as-usual. Wider scatterplot showing results
reflecting input parameter uncertainty and heterogeneity. Narrower scatterplot reflecting only input parameter uncertainty
Blakely et al. BMC Health Services Research  (2015) 15:306 Page 7 of 12
provisional diagnosis to surgery component of the inter-
vention (less health gain and also less cost). Varying the
discount rate had a moderate impact in an expected
manner.
If we excluded the expected population morbidity, the
QALYsDW gained increased due to no assumed loss of
quality of life in survivors, and therefore the ICER re-
duced by 27 %. A life-years gained analysis resulted in a
similar ICER.
Scaling up and down the health system costs (exclud-
ing chemotherapy) had a modest impact only, but ex-
cluding the assumed increased referrals to dieticians and
social workers reduced costs by 23 %. Finally, our most
comprehensive model included unrelated health system
costs into the future, and if these are excluded the (dis-
counted at 3 %) costs decrease by 21 %.
Ethnic equity analysis
Applying non-Māori least deprived mortality and non-
Māori average background morbidity to both Māori and
non-Māori resulted in an increase in the QALYsDW
gained by 47 % for Māori and a reduction in the ICER
by 25 % such that it becomes lower for Māori compared
to non-Māori ($15,100 compared to $18,500; Table 4).
One-way sensitivity analyses
Uncertainty in the following four input parameters has
the biggest impact on uncertainty in model outputs
(Figs. 3 and 4): the proportionate reduction in days to
chemotherapy (QALYsDW and ICER), increased coverage
of chemotherapy (QALYsDW, cost and ICER), improved
survival from getting chemotherapy quicker (QALYsDW
and ICER), and cost per patient of chemotherapy (cost
and ICER).
Discussion
We find that CCCs, for colon cancer stage III at least,
are cost-effective for a willingness to pay of NZ$20,000
(about US$16,500; using mean value) or NZ$25,000
(about US$ 21,000; using the upper uncertainty limit).
The major drivers of health gain come from increased
coverage of effective treatments and reduced time to ef-
fective treatments via better coordination of care, a con-
clusion that should be generalisable to other CCC
programmes. Impacts through changes in quality of life,
if just during the delivery of the programme itself, are
unlikely to be a major driver of health gains. We found
substantial heterogeneity, in that health gains were
greater and costs less for younger patients resulting in
better cost-effectiveness. However, this cost variation by
age may not be generalisable to other CCC interven-
tions, as in our evaluation young people in the ‘business-
as-usual’ comparator were already almost all receiving
chemotherapy – the key cost driver. Social inequalities
in health are a major policy concern worldwide [32].
There are large health inequalities between Māori and
non-Māori in New Zealand [33], including for colon
cancer survival [20]. Our evaluation suggests that CCC
would achieve greater health gains for Māori patients
due to lower receipt of chemotherapy and longer wait
times in the business-as-usual arm. However, this find-
ing is contingent on our assumption that the propor-
tionate increase in chemotherapy coverage, and
Table 4 Main model analysis by sex, age, ethnicity, and
deprivation: incremental costs, QALYsDW gained and ICERs for











Males $2050 0.118 $17,400
Females $2520 0.121 $20,800
By age
< 65 years $1620 0.172 $9,400
≥ 65 years $2490 0.106 $23,600
By ethnicity by age
Māori $3420 0.171 $20,000
< 65 years $2810 0.223 $12,600
≥ 65 years $3730 0.147 $25,300
Non-Māori $2220 0.118 $18,800
< 65 years $1510 0.167 $9,000








Equity analysis: using non-Māori least deprived mortality and non-Māori
average background morbidity
By ethnicity by age (percentage variation from equivalent above standard
analysis)
Māori $3,780 (11 %) 0.251 (47 %) $15,100 (−25 %)
< 65 years $3,250 (16 %) 0.317 (42 %) $10,300 (−18 %)
≥ 65 years $4,070 (9 %) 0.222 (51 %) $18,400 (−27 %)
Non-Māori $2,240 (1 %) 0.121 (3 %) $18,500 (−2 %)
< 65 years $1,540 (2 %) 0.171 (2 %) $9,000 (0 %)
≥ 65 years $2,430 (0 %) 0.107 (3 %) $22,800 (−2 %)
All models are expected value only; there is no parameter uncertainty
Dollars are NZ$, for the year 2011. All costs and benefits discounted at 3 %
per annum. All values rounded to three meaningful decimal places
aNote that these results differ slightly from those in Table 3 due to not
including uncertainty about parameters (due to long run time of models).
Results in Table 3 are the preferred results, but the results in this table should
be compared to this expected value analysis result which used the same
modelling strategy
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proportionate reduction in time to chemotherapy from
CCC, is constant across ethnic groups. When we con-
duct an equity analysis with background mortality and
morbidity rates held constant by ethnic group, we find
greater ‘equity weighted’ health gains for Māori and a
comparable ICER between Māori and non-Māori. In-
corporating equity in cost-effectiveness evaluations is an
under-developed area. Previous researchers have also
attempted incorporating equity [34]; our approach
should be taken as one possible method to consider and
subject to further scrutiny.
Health economic decision models are conducted to as-
sist prioritisation of resources. Questions that decision-
makers want answered often require collating data that
is uncertain, and making justified assumptions. Whilst
we have high quality New Zealand data for many of the
baseline parameters in our model (e.g. survival by socio-
demographics), our evaluation still has many uncertain
input parameters (e.g. the effect of a CCC). Despite that,
we believe that we have demonstrated that with careful
parameter specification and most particularly inclusion
of (appropriately) wide uncertainty can still lead to
useful conclusions. Through our scenario (Table 5) and
sensitivity analyses (Figs. 3 and 4), we think we have pro-
vided enough alternative analyses for interested readers
who disagree with our parameterisation and assumptions
to find something that accords with their ‘prior’. Regard-
ing our own best estimates and’prior’, we conclude that
CCC for stage III colon cancer at least is probably cost-
effective and pro-equity.
We are aware of three cost-effectiveness analyses
(CEAs; two for breast cancer and one for any ter-
minal cancer patient) [15–17] and one cost-benefit
analysis [35] of CCC-type interventions. It is difficult
to compare our results with these previous evalua-
tions due to the different cancers, variation in where
the CCC intervention was provided in the cancer care
pathway, and different approaches in the economic
analyses. In short, one study found the CCC-type inter-
vention was no different in cost to usual care and did im-
prove quality of life indicators [17], another found no
improvement in quality of life outcomes but a reduction
in costs with the intervention [15], and a third showed an
incremental cost per life year gained of $US 95,625 (from
Table 5 Scenario analyses: incremental costs, QALYsDW gained and ICERs for the CCC intervention compared to business-as-usual
(percentage difference to expected value analysis in parentheses)






Expected value analysisa $2,250 0.111 $20,200
Varying phases of CCC intervention
a. CCC from diagnosis to surgery only $80 (−96 %) 0.009 (−92 %) $9,100 (−55 %)
b. CCC from surgery to chemotherapy only $2,170 (−4 %) 0.104 (−6 %) $20,900 (3 %)
Variations to discount rate
c. 0 % per annum discount rate $2,520 (12 %) 0.148 (33 %) $17,100 (−15 %)
d. 6 % per annum discount rate $2,080 (−8 %) 0.088 (−21 %) $23,600 (17 %)
Variation to epidemiological parameters
e. Set all DWs (incl pYLDs) to zero (= ‘life years’ gained) $2,250 (0 %) 0.150 (35 %) $15,000 (−26 %)
f. Exclude improved quality of life impact of CCC $2,250 (0 %) 0.100 (−10 %) $22,400 (11 %)
g. Exclude improved survival due to quicker to surgery $2,240 (0 %) 0.107 (−4 %) $21,000 (4 %)
h. Exclude improved survival due to quicker to chemotherapy $2,130 (−5 %) 0.084 (−24 %) $25,200 (25 %)
i. Exclude increasing % of patients getting chemotherapy $800 (−64 %) 0.061 (−45 %) $13,000 (−36 %)
j. Exclude oxaliplatin $2,020 (−10 %) 0.095 (−14 %) $21,300 (5 %)
Variation to cost parameters
k. Scale all health system costs up 20 % $2330 (4 %) 0.111 (0 %) $20900 (3 %)
l. Scale all health system costs down 20 % $2170 (−4 %) 0.111 (0 %) $19500 (−3 %)
m. Exclude dietician and social worker intervention costs $1730 (−23 %) 0.111 (0 %) $15600 (−23 %)
n. Exclude unrelated health system costs (i.e. include costs up to cure time only) $1780 (−21 %) 0.111 (0 %) $16000 (−21 %)
All models are expected value only; there is no parameter uncertainty
Dollars are NZ$, for the year 2011. Unless stated otherwise, all costs and benefits discounted at 3 % per annum. All values rounded to three meaningful
decimal places
pYLDs prevalent years of life lived with disability, which is used as the ‘expected’ amount of morbidity by sex, age and ethnicity
aNote that these results differ slightly from those in Table 3 due to not including uncertainty about parameters (due to long run time of models). Results in
Table 3 are the preferred results, but the results in this table should be compared to this expected value analysis which used the same modelling strategy
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abnormal screening to diagnostic follow-up for breast can-
cer patients). Unlike our model, one of the CEAs assessed
the effect of patient navigators in a specific population
(low-income, ethnic minority and 40 years or older) [15];
a strength of our evaluation is the explicit incorporation
of heterogeneity by sex, age, ethnicity and deprivation per-
mitting evaluations by type of patient (Table 4). Other
relative strengths of our evaluation include the systematic
reviews for each key input parameter (although the studies
found were often poor quality), input obtained from ex-
perts where there was a lack of published data, clear ex-
planations for assumptions where they were made
(Additional file 2), inclusion of both morbidity and
mortality, and probabilistic sensitivity analysis. In con-
trast, two of the CEAs [15, 17] were conducted
alongside randomised controlled trials with access to
raw data for quality of life measures and cost data;
we relied on data collected from a resource use sur-
vey for our cost data.
We cannot directly generalise our evaluation for stage
III colon cancer patients to other settings, but we may
be able to extrapolate in terms of principle. For ex-
ample, we would expect health gains to be less if there
is already good coordination in place through means
other than CCC such as well functioning multi-
disciplinary meetings and good IT systems for tracking
Fig. 3 Tornado plot for QALYs gained (top axis) and cost (bottom axis) for 2.5th and 97.5th percentile values of input parameters. Above values
are for single parameter values only. That is, the 2.5th (or 97.5th) percentile value of the parameter itself, and the mean expected value of all
remaining parameters in the table, are modelled. There is no modelled parameter uncertainty. The estimates are averaged over heterogeneity
and stochastic variation. EMR = excess mortality rate (due to cancer); CCC = cancer care coordinator
Fig. 4 Tornado plot for ICER for 2.5th and 97.5th percentile values of input parameters. EMR = excess mortality rate (due to cancer); CCC = cancer
care coordinator
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patient care. However, costs would also be less, mean-
ing the ICER may not be too different. Second, our
evaluation demonstrates that increasing receipt of
effective treatments and reducing time to effective
treatments is the major benefit of a CCC programme,
not the quality of life impacts per se.
Whilst decision-makers need information now, and our
study responds to that imperative, there is considerable
uncertainty in the input parameters (as shown in Figs. 2, 3
and 4). Regarding stage III colon cancer per se, it is the
uncertainty in these three intervention effects that matters
most: how much the CCC reduces time to chemotherapy,
what proportion of those eligible for chemotherapy but
not receiving it pre-CCC receive it post-CCC; and the im-
provement in survival from getting chemotherapy quicker.
Research, such as randomised trials of CCC, to estimate
these parameters with greater accuracy would increase the
accuracy of modelling such as our study. Second, under-
taking similar evaluations for different phases of the can-
cer patient journey (e.g. support during remission) and
different cancers (e.g. lung cancer where treatment effi-
cacy is less, or breast cancer where survival is better and
reducing time to treatment is perhaps not so critical) is
necessary to have a greater understanding of where CCC
should be prioritised within the full range of cancer
services.
Conclusions
For stage III colon cancer, we estimate that CCCs do
improve health outcomes, and is a cost-effective inter-
vention for younger patients at least. It also appears –
in the New Zealand context at least – to afford as much
if not more benefit to Māori patients who usually have
worse outcomes, with approximately the same cost-
effectiveness as the general population. Thus, the inter-
vention is probably pro-equity. Generalising to CCC for
other phases of the cancer patient journey, and other
cancers, is difficult due to differing baseline patient
journeys, survival rates and treatment efficacy. How-
ever, our study suggests that CCCs that increase receipt
of, and minimise time to, effective treatments should be
prioritised.
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